… Prostate cancer (PCa) is one of the most common cancers in men. In the year 2020, an …
-resistant prostate cancer (mCRPC). The long-term prognosis for patients with mCRPC is poor, …

… the management of advanced prostate cancer provides a range of treatment options with
notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the …

… prostate cancer (mCRPC) … mCRPC and mutations in DNA damage repair genes has added
to the treatment armamentarium and improved personalized treatments for prostate cancer. …

… -scale mCRPC trials. Pembro showed preliminary antitumor activity in PD-L1+ mCRPC in …
of pembro monotherapy in docetaxel-refractory mCRPC (NCT02787005). Methods: Cohorts …

… /kg of avelumab in pts with mCRPC who had progressive disease (… Prostate cancer working
group 2 criteria were used to … on a population of pts with mCRPC. Immune analysis is under …

… DDR = defective DNA repair; FPKM = Fragments Per Kilobase of transcript per Million
mapped reads; mCRPC = metastatic castration-resistant prostate cancer; PSMA = …

… of metastatic castration-resistant prostate cancer (mCRPC), increasing options available to
… of men with mCRPC. Toward this effort, recent studies evaluated mCRPC treatment patterns …

… Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease are …

… Prostate cancer is the most common non-cutaneous cancer … prostate cancer (CRPC), or
metastatic CRPC (mCRPC), … in addition to ADT in the mCRPC setting has grown quickly, starting …

… metastatic castration-resistant prostate cancer (mCRPC), of … types of cancer, but only a
marginal benefit for mCRPC, at … nature of the prostate tumor microenvironment, including …